Flutiform failure in Phase III COPD trial a setback for Mundipharma and Vectura

31 August 2016

The UK’s pharma company Mundipharma and inhaled therapies developer Vectura (LSE: VEC) said that Flutiform has failed to meet the primary endpoint of a Phase III trial in chronic obstructive pulmonary disease (COPD).

Vectura’s share price dropped by almost 9% on Tuesday as the news was announced that the trial had failed to meet the goal of demonstrating statistically significant superiority in the reduction of annualised rates of moderate and severe COPD exacerbations when compared to mono-component long-acting beta-agonists (LABA) treatment alone.

Mundipharma carried out this Phase III study to support a filing to expand the approved indication for the regular treatment of asthma of Flutiform in Europe to include COPD, and is now analyzing the trial’s other endpoints.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK